Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell …

Context Rivaroxaban and ticagrelor are two common drugs for the treatment of atrial
fibrillation and acute coronary syndrome. However, the drug–drug interaction between them …

Background Currently, there are no direct comparisons of apixaban and rivaroxaban, two
new oral direct factor Xa inhibitors approved for management of thromboembolic disorders …

Plasma concentrations of direct oral anticoagulants (DOAC) are potentially affected because
of drug-drug interactions (DDI) with anticancer treatment as a result of inhibition or induction …

Background The risk of venous thromboembolism (VTE) is increased 7-fold in patients with
cancer than in those without. Low-molecular-weight heparin is the standard treatment for …

Background The concurrent administration of dronedarone and oral anti-coagulants is
common because both are used in managing atrial fibrillation (AF). Dronedarone is a …

The pharmacokinetics (PK) of rivaroxaban have been studied in different populations, and
there were differences in the PK parameters. However, most of these studies were …

Almonertinib was included in the first‐line treatment of non‐small cell lung cancer with
EGFR T790M mutations by the Chinese Society of Clinical Oncology in 2021. Considering …

Background: Apixaban is an oral, potent, highly selective, reversible and direct inhibitor of
activated coagulation factor X, that is the end point of the intrinsic and extrinsic coagulation …

A simple, sensitive and accurate LC–MS/MS method was developed and validated for the
simultaneous quantification of apixaban (APB) and metformin (MET) in rat plasma using …